<DOC>
	<DOCNO>NCT01593371</DOCNO>
	<brief_summary>Oral hypoglycemic agent encompass mainstay treatment majority patient type 2 diabetes . Thiazolidinediones ( pioglitazone ) Biguanides ( metformin ) , two major group hypoglycemic medication function via different pathway , effective short- long-term glycemic control . These medication diminish least delay long term micro- macrovascular complication associate prolonged insulin resistance although different rate . The mechanisms aim achieve , nevertheless , remain largely unclear . With adipokines play key role development insulin resistance atherosclerosis , oral hypoglycemic agent might regulate substance direct indirect route .</brief_summary>
	<brief_title>Comparison Metformin Pioglitazone Effects Adipokines Concentrations Newly Diagnosed Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Newly diagnose type 2 diabetes patient base American Diabetes Association criterion ( 2011 ) diagnosis diabetes previous intake oral hypoglycemic agent treatment diabetes hyperglycemia associate condition intake glucocorticoid past one year major illness heart , lung , kidney , liver .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Adipokines</keyword>
	<keyword>leptin</keyword>
	<keyword>chemerin</keyword>
	<keyword>omentin</keyword>
	<keyword>metformin</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>